STE Cash & equivalents
Cash & equivalents at Steris rose to $440M in fiscal 2026, the highest in the 5 years reported, from $172M in 2025.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · EDGAR CompanyFacts · CIK 1757898 · EDGAR ↗ · FY2022–FY2026 · ANNUAL
FY2026$440M
FY2025 $172M
HIGH$440M FY2026
LOW$172M FY2025
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2026 | $440M | +$268M |
| FY2025 | $172M | $-35M |
| FY2024 | $207M | $-1M |
| FY2023 | $208M | $-140M |
| FY2022 | $348M | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · STE company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.